ICU Medical (NASDAQ:ICUI) Updates FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.550-7.250 for the period, compared to the consensus earnings per share estimate of 7.130. The company issued revenue guidance of -.

ICU Medical Stock Down 2.9 %

ICU Medical stock traded down $4.52 during trading on Thursday, reaching $149.75. The stock had a trading volume of 388,345 shares, compared to its average volume of 201,601. ICU Medical has a 52-week low of $93.36 and a 52-week high of $196.26. The business has a 50 day moving average price of $160.70 and a 200 day moving average price of $166.21. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.67 billion, a PE ratio of -32.77 and a beta of 0.63.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.24. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. On average, analysts predict that ICU Medical will post 4.11 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ICUI shares. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Wednesday, December 11th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. KeyCorp boosted their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $199.67.

Insider Activity

In other news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.